1. Reduction in skin microvascular density and changes in vessel morphology in patients treated with sunitinib
- Author
-
Yvo M. Smulders, Etto C. Eringa, Astrid A.M. van der Veldt, Victor W.M. van Hinsbergh, Erik H. Serné, Michiel P. de Boer, Epie Boven, Alfons J.M. van den Eertwegh, Internal medicine, Medical oncology, Physiology, CCA - Innovative therapy, EMGO - Lifestyle, overweight and diabetes, and ICaR - Ischemia and repair
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Indoles ,Ambulatory blood pressure ,Side effect ,Urology ,Angiogenesis Inhibitors ,Microcirculation ,chemistry.chemical_compound ,Internal medicine ,Sunitinib ,medicine ,Humans ,Pyrroles ,Pharmacology (medical) ,Aged ,Skin ,Aged, 80 and over ,Pharmacology ,Predictive marker ,business.industry ,Microvascular Density ,Middle Aged ,Kidney Neoplasms ,Capillaries ,Vascular endothelial growth factor ,Blood pressure ,Endocrinology ,Oncology ,chemistry ,Hypertension ,Female ,business ,medicine.drug - Abstract
Hypertension is a common side effect in cancer patients treated with inhibitors of vascular endothelial growth factor/vascular endothelial growth factor receptor-2 signaling and may represent a marker of clinical benefit. Functional rarefaction (a decrease in perfused microvessels) or structural rarefaction (a reduction in anatomic capillary density) may play an important role in the development of hypertension. We investigated whether sunitinib caused impairment of microvascular function and/or reduction of capillary density in patients with metastatic renal cell cancer (mRCC). Sixteen mRCC patients were treated with sunitinib (50 mg/day). Assessments of 24-h ambulatory blood pressure, microvascular endothelial function by laser Doppler fluxmetry, and capillary density by capillary microscopy were performed at baseline and days 14 and 28. Median blood pressure had increased on day 14 (systolic 10 mmHg, P
- Published
- 2010